Novel therapies for an old virus: treatment of RSV infections in the 21st Century

Expert Rev Anti Infect Ther. 2009 Nov;7(9):1125-9. doi: 10.1586/eri.09.90.

Abstract

Respiratory syncytial virus (RSV) is a pathogen whose existence has been known for decades, causing mild-to-severe upper and lower respiratory tract infections that bear the risk of subsequent asthma and can even lead to a fatal outcome. RSV infects all groups of patients and is a major cause of hospitalization in children and in the elderly. This review briefly summarizes the current status of RSV drug development and clinical trials for drugs available for the treatment of RSV infections.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use*
  • Benzimidazoles / therapeutic use
  • Clinical Trials as Topic
  • Drug Discovery*
  • Glycosaminoglycans / antagonists & inhibitors
  • Glycosaminoglycans / pharmacology
  • Humans
  • Lipopolysaccharide Receptors / metabolism
  • RNA, Small Interfering / therapeutic use
  • Respiratory Syncytial Virus Infections / drug therapy*
  • Respiratory Syncytial Virus, Human / drug effects*
  • Viral Fusion Proteins / antagonists & inhibitors
  • Viral Fusion Proteins / pharmacology
  • Virus Attachment / drug effects
  • Virus Replication / drug effects

Substances

  • Antiviral Agents
  • Benzimidazoles
  • Glycosaminoglycans
  • Lipopolysaccharide Receptors
  • RNA, Small Interfering
  • Viral Fusion Proteins